Plasma and CSF Abeta peptides in late-onset major depression
Plasma and CSF Abeta peptides in late-onset major depression
批准号:
7781322
负责人:
Nunzio Pomara
金额:
$30.14万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2012-02-29
关键词:
AgeAllelesAlzheimer&aposs DiseaseAmyloid beta-ProteinApolipoprotein EBiological MarkersCerebrospinal FluidClinicalCognitiveDevelopmentDiagnosisDiseaseElderlyEtiologyExhibitsGenotypeGoalsImpaired cognitionIndividualLongitudinal StudiesMajor Depressive DisorderMeasuresMoodsOutcomePathologicPeptidesPerformancePhasePilot ProjectsPlasmaRelative (related person)ReportingResearch PersonnelRoleSex EducationSubgroupTestingTimebasecognitive functiondepressive symptomsfollow-upgeriatric major depressionpre-clinicalprogramsprospective
中文摘要
描述(由申请人提供):晚发性老年重度抑郁症(晚发性LLMD)是一种病因和预后方面的异质性疾病。纵向和尸检研究都发现,晚发性LLMD的一部分老年人在第一次抑郁发作时认知功能完好无损,他们将在相对较短的随访期内发展为进行性认知衰退和/或阿尔茨海默病(AD)的临床和组织病理学诊断。病理性AD标准的制定需要几十年的时间,这意味着抑郁发作可能代表了一部分人的AD临床前或前驱期。然而,目前还没有生物标志物来识别那些患有前驱AD的晚发性LLMD患者。我们小组和其他人在健康老年人中进行的研究结果表明,基线血浆淀粉样β多肽-mA(A/?42)水平较高,A?42/A/?40比值较高,A?42在纵向随访期间下降较多,与认知功能下降和/或AD的发生有关。我们的横断面初步研究也有证据表明,患有LLMD的老年患者血浆A/?42和A$/A?40比值升高,严重抑郁症患者的脑脊液A/?42水平也升高。基于这些早期的提示性发现,这项建议的主要目标是:(1)进行一项为期3年的纵向研究,以检验以下假设:与对照组相比,晚发性LLMD老年患者的血浆A/942水平和A#42/A?40比率更高,而A#42/A?42的水平更大;(2)研究A/042的测量是否与迟发性LLMD老年个体的认知功能下降和/或AD的发展有关。另一个目标是确定在一组受试者中,血浆A/FF42水平的变化是否与脑脊液(CSF)A/?42的类似变化平行。如果这些假设得到证实,那么血浆A/?42的测定可能成为一种容易获得的标记物,用来识别那些可能患有前驱AD的晚发性LLMD患者。
英文摘要
DESCRIPTION (provided by applicant): Late-onset late life major depression (late-onset LLMD) is a heterogeneous disorder with respect to etiology and outcome. Both longitudinal and post-mortem studies have found that a subset of elderly individuals with late-onset LLMD who are cognitively intact at the time of their first depressive episode will develop progressive cognitive decline and/or a clinical and histopathologic diagnosis of Alzheimer's disease (AD) within relatively brief follow-up periods. The many decades required for the pathologic AD criteria to develop implies that the depressive episode may represent a preclinical or prodromal phase of AD in a subset of individuals. However, there are presently no biological markers to identify those individuals with late-onset LLMD who have prodromal AD. Results from studies in healthy elderly conducted by our group and others suggest that higher baseline plasma amyloid beta peptide-Ma (A/?42) level, higher A¿42/A/?40 ratios and greater reductions in A¿42 during longitudinal follow-up, are associated with greater cognitive decline and/or incident AD. There is also evidence from our cross-sectional pilot study of elevated plasma A/?42 and A$42/A¿40 ratio in elderly individuals with LLMD, and elevated CSF A/?42 levels have also been reported previously in individuals with major depression. Based on these earlier suggestive findings, the major objectives of this proposal are: (1) to conduct a 3-year longitudinal study to test the hypothesis that elderly individuals with late-onset LLMD will have higher plasma A/942 level and A#42/A¿40 ratio and greater reductions in A¿42 during longitudinal follow-up relative to controls, and (2) to examine whether measures of A/042 will be associated with greater cognitive decline and/or the development of AD in elderly individuals with late-onset LLMD. Another goal is to determine if changes in plasma A/ff42 levels are paralleled by similar changes in cerebrospinal fluid (CSF) A/?42 in a subset of subjects. If these hypotheses are confirmed, then the determination of plasma A/?42 might become an easily obtainable marker to identify those individuals with late-onset LLMD who may have prodromal AD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease risk
-
批准号:10468212
-
项目类别:
-
资助金额:$79.45万
-
财政年份:2021
-
负责人:Nunzio Pomara
-
依托单位:
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease risk
-
批准号:10301716
-
项目类别:
-
资助金额:$78.51万
-
财政年份:2021
-
负责人:Nunzio Pomara
-
依托单位:
Depression treatment and Aβ dynamics: A study of Alzheimer’s disease risk
-
批准号:10681339
-
项目类别:
-
资助金额:$78.24万
-
财政年份:2021
-
负责人:Nunzio Pomara
-
依托单位:
Plasma and CSF Abeta peptides in late-onset major depression
-
批准号:8033160
-
项目类别:
-
资助金额:$27.4万
-
财政年份:2007
-
负责人:Nunzio Pomara
-
依托单位:
Plasma and CSF Abeta peptides in late-onset major depression
-
批准号:7208814
-
项目类别:
-
资助金额:$37.52万
-
财政年份:2007
-
负责人:Nunzio Pomara
-
依托单位:
Plasma and CSF Abeta peptides in late-onset major depression
-
批准号:7568991
-
项目类别:
-
资助金额:$27.73万
-
财政年份:2007
-
负责人:Nunzio Pomara
-
依托单位:
LONGTERM LORAZEPAM USE AND ACUTE TOXICITY IN THE ELDERLY
-
批准号:7605694
-
项目类别:
-
资助金额:$0.47万
-
财政年份:2007
-
负责人:Nunzio Pomara
-
依托单位:
LONGTERM LORAZEPAM USE AND ACUTE TOXICITY IN THE ELDERLY
-
批准号:7378260
-
项目类别:
-
资助金额:$1.54万
-
财政年份:2006
-
负责人:Nunzio Pomara
-
依托单位:
LONGTERM LORAZEPAM USE AND ACUTE TOXICITY IN THE ELDERLY
-
批准号:7207080
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2005
-
负责人:Nunzio Pomara
-
依托单位:
Longterm Lorazepam Use and Acute Toxicity in the Elderly
-
批准号:6974298
-
项目类别:
-
资助金额:$0.97万
-
财政年份:2004
-
负责人:Nunzio Pomara
-
依托单位:
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
-
批准号:6841930
-
项目类别:
-
资助金额:$27.45万
-
财政年份:2001
-
负责人:Nunzio Pomara
-
依托单位:
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
-
批准号:6499284
-
项目类别:
-
资助金额:$26.65万
-
财政年份:2001
-
负责人:Nunzio Pomara
-
依托单位:
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
-
批准号:6697520
-
项目类别:
-
资助金额:$27.18万
-
财政年份:2001
-
负责人:Nunzio Pomara
-
依托单位:
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
-
批准号:6629223
-
项目类别:
-
资助金额:$26.91万
-
财政年份:2001
-
负责人:Nunzio Pomara
-
依托单位:
LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
-
批准号:6287040
-
项目类别:
-
资助金额:$28.65万
-
财政年份:2001
-
负责人:Nunzio Pomara
-
依托单位:
APOE E4 AND LORAZEPAM EFFECTS ON ELDERLY
-
批准号:2035629
-
项目类别:
-
资助金额:$30.48万
-
财政年份:1997
-
负责人:Nunzio Pomara
-
依托单位:
APOE E4 AND LORAZEPAM EFFECTS ON ELDERLY
-
批准号:2890923
-
项目类别:
-
资助金额:$18.66万
-
财政年份:1997
-
负责人:Nunzio Pomara
-
依托单位:
APOE E4 AND LORAZEPAM EFFECTS ON ELDERLY
-
批准号:2675619
-
项目类别:
-
资助金额:$30.62万
-
财政年份:1997
-
负责人:Nunzio Pomara
-
依托单位:
LORAZEPAM AND ALPRAZOLAM: PERFORMANCE EFFECTS IN ELDERLY
-
批准号:2245460
-
项目类别:
-
资助金额:$19.95万
-
财政年份:1991
-
负责人:Nunzio Pomara
-
依托单位:
LORAZEPAM AND ALPRAZOLAM: PERFORMANCE EFFECTS IN ELDERLY
-
批准号:3381639
-
项目类别:
-
资助金额:$18.61万
-
财政年份:1991
-
负责人:Nunzio Pomara
-
依托单位:
海外基金